Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJohn F Thompson, Seng-Jaw Soong, Charles M Balch, et al.The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.Cancer Cell|October 2, 2020
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesFloris Dammeijer, Mandy van Gulijk, Evalyn E Mulder, et al.Cell Research|September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.Journal of Medical Genetics|June 9, 2017
Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcomaFanélie Jouenne, Isaure Chauvot de Beauchene, Emeline Bollaert, et al.The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.Pageof 4